PD-1 targeted IL-15/IL-15Rα Fc fusion proteins with improved properties
John Desjarlais, Pasadena, CA (US); Matthew Bernett, Pasadena, CA (US); Michael Hedvat, Pasadena, CA (US); Rajat Varma, Pasadena, CA (US); Suzanne Schubbert, Pasadena, CA (US); Christine Bonzon, Pasadena, CA (US); Rumana Rashid, Pasadena, CA (US); Juan Diaz, Pasadena, CA (US); Patrick Holder, South San Francisco, CA (US); and Christine Huang, South San Francisco, CA (US)
Assigned to GENENTECH, INC., South San Francisco, CA (US); and XENCOR, INC., Pasadena, CA (US)
Filed by Genentech, Inc., South San Francisco, CA (US); and Xencor, Inc., Pasadena, CA (US)
Filed on Oct. 9, 2020, as Appl. No. 17/067,508.
Claims priority of provisional application 63/011,208, filed on Apr. 16, 2020.
Claims priority of provisional application 62/914,265, filed on Oct. 11, 2019.
Claims priority of provisional application 62/914,317, filed on Oct. 11, 2019.
Prior Publication US 2021/0230243 A1, Jul. 29, 2021
1. A composition comprising a variant IL-15 protein as compared to SEQ ID NO:2, said variant IL-15 protein comprising an amino acid modification selected from the group consisting of N71Q, N79Q, N112Q, S114del and S114A.